# US 2026/0085311 A1 · Compositions and methods for reducing rna levels

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0085311 A1
- Document ID: US20260085311A1
- Status: Published application
- Kind: A1
- Application number: 18/876,098
- Filed: 2023-06-20
- Published: 2026-03-26
- Earliest claimed: 2022-06-21
- Assignees: The Regents of the University of California
- Applicants: The Regents of the University of California
- Inventors: Liana Lareau; Fyodor Urnov; Ma. Carmelle Catamura
- Web page: https://patentgrep.com/patent/US20260085311A1

## CPC

- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C12N 9/1276: {RNA-directed DNA polymerase (2.7.7.49), i.e. reverse transcriptase or telomerase}
- C12N 9/222: {Clustered regularly interspaced short palindromic repeats [CRISPR]-associated [CAS] enzymes}
- C12N 9/226: {Class 2 CAS enzyme complex, e.g. single CAS protein}
- C12N 9/78: acting on carbon to nitrogen bonds other than peptide bonds (3.5)
- C12N 15/52: Genes encoding for enzymes or proenzymes
- C12N 15/63: Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12Y 207/07049: RNA-directed DNA polymerase (2.7.7.49), i.e. telomerase or reverse-transcriptase
- C12Y 305/04004: Adenosine deaminase (3.5.4.4)
- C12Y 305/04005: Cytidine deaminase (3.5.4.5)
- C12N 9/22: Ribonucleases {[RNase]; Deoxyribonucleases [DNase]}
- C12N 2310/20: involving clustered regularly interspaced short palindromic repeats [CRISPR]
- C12N 2320/33: Alteration of splicing
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12Y: ENZYMES

## Abstract

The present disclosure provides methods for reducing the level of an RNA transcript from a target nucleic acid. The present disclosure provides methods of treating a disease that results from or is caused by a toxic gain-of-function protein. The present disclosure provides systems and compositions for carrying out a method of the present disclosure.

## Claims

### Claim 1

A method of reducing the level of an RNA transcript from a target nucleic acid, the method comprising modifying the nucleotide sequence of the target nucleic acid such that a spliced mRNA product of the modified target nucleic acid comprises a stop codon that is not present in a spliced mRNA transcript of the unmodified target nucleic acid and wherein, as a result of the stop codon, the spliced mRNA product undergoes nonsense-mediated mRNA decay, thereby reducing the level of the RNA transcript.

### Claim 2 (depends on 1)

The method of claim 1, wherein the spliced mRNA product of the modified target nucleic acid comprises a stop codon induced by a frameshift caused by the inclusion of an exon not present in the spliced mRNA of the unmodified target nucleic acid.

### Claim 3 (depends on 2)

The method of claim 2, wherein said modifying comprises: (a) modifying the nucleotide sequence in the target nucleic acid to include a splice dinucleotide that is not present in the unmodified target nucleic acid, optionally wherein the splice dinucleotide is an AG dinucleotide or a GT dinucleotide, (b) modifying a polypyrimidine tract that is immediately 5′ of an endogenous AG dinucleotide, generating a modified AG dinucleotide-containing sequence, such that a spliceosome in a cell would recognize the modified AG dinucleotide-containing sequence as a splice acceptor dinucleotide, and/or (c) modifying a consensus sequence within 10 nucleotides of an endogenous GT dinucleotide, generating a modified GT dinucleotide-containing sequence, such that a spliceosome in a cell would recognize the modified GT dinucleotide-containing sequence as a splice donor dinucleotide.

### Claim at position 4

4-5. (canceled)

### Claim 6 (depends on 1)

The method of claim 1, comprising modifying an exon of the target nucleic acid such that the modified target nucleic acid includes a stop codon that is not present in an exon of the unmodified target nucleic acid.

### Claim 7 (depends on 1)

The method of claim 1, wherein modifying comprises contacting the target nucleic acid with a) a CRISPR-Cas effector polypeptide or a fusion CRISPR-Cas effector polypeptide comprising: i) a CRISPR-Cas effector polypeptide; and ii) one or more heterologous polypeptides; and (b) a guide nucleic acid, wherein the guide nucleic acid comprises: i) a targeting region that comprises a nucleotide sequence that binds to a target sequence in the target nucleic acid; and ii) a protein-binding region that binds to the CRISPR-Cas effector polypeptide.

### Claim 8 (depends on 7)

The method of claim 7, further comprising contacting the target nucleic acid with a donor nucleic acid that comprises a nucleotide sequence that includes the modification that results in the stop codon.

### Claim at position 8

9-10. (canceled)

### Claim 11 (depends on 7)

The method of claim 7, wherein the one or more heterologous polypeptides comprises a reverse transcriptase, a cytidine deaminase, or an adenine deaminase.

### Claim 12 (depends on 11)

The method of claim 11, wherein the CRISPR-Cas effector polypeptide is a nickase.

### Claim at position 11

13-15. (canceled)

### Claim 16 (depends on 1)

The method of claim 1, wherein the target nucleic acid is present in a eukaryotic cell.

### Claim 17 (depends on 16)

The method of claim 16, wherein the eukaryotic cell is in vitro.

### Claim 18 (depends on 16)

The method of claim 16, wherein the eukaryotic cell is in vivo.

### Claim 19 (depends on 16)

The method of claim 16, wherein the eukaryotic cell comprises a disease-associated mutation-containing allele and a corresponding wild-type allele that does not comprise the disease-associated mutation, and wherein the disease-associated mutation-containing allele comprises the target nucleic acid.

### Claim 20 (depends on 19)

The method of claim 19, wherein the disease-associated mutation-containing allele comprises a single nucleotide polymorphism (SNP) that is not present in the corresponding wild-type allele, and wherein the method comprises contacting the target nucleic acid with: a) a CRISPR-Cas effector polypeptide or a fusion polypeptide comprising a CRISPR-Cas effector polypeptide; and b) a guide nucleic acid, wherein the guide nucleic acid comprises: i) a targeting region that comprises a nucleotide sequence that binds to a target sequence in the target nucleic acid, wherein the target sequence comprises the SNP; and ii) a protein-binding region that binds to the CRISPR-Cas effector polypeptide.

### Claim 21 (depends on 1)

The method of claim 1, wherein the target nucleic acid encodes a toxic gain-of-function polypeptide.

### Claim 22

(canceled)

### Claim 23

A method for treating a disease caused by a toxic gain-of-function polypeptide in an individual, the method comprising reducing the level of an RNA transcript from a target nucleic acid encoding the toxic gain-of-function polypeptide, comprising modifying the nucleotide sequence of the target nucleic acid such that a spliced mRNA product of the modified target nucleic acid comprises an exon that comprises a stop codon not present in a spliced mRNA product of the unmodified target nucleic acid, wherein the spliced mRNA product undergoes nonsense-mediated mRNA decay, thereby reducing the level of the RNA transcript and treating the disease.

### Claim 24 (depends on 23)

The method of claim 23, wherein the disease is a trinucleotide repeat expansion disease, a tetranucleotide repeat expansion disease, or a hexanucleotide repeat expansion disease.

### Claim at position 21

25-26. (canceled)

### Claim 27

A system for reducing the level of an RNA transcript from a target nucleic acid in a eukaryotic cell, the system comprising:
a) a CRISPR-Cas effector polypeptide, or a nucleic acid encoding a CRISPR-Cas effector polypeptide, or a CRISPR-Cas effector fusion polypeptide, or a nucleic acid encoding a CRISPR-Cas effector fusion polypeptide, wherein the CRISPR-Cas effector fusion polypeptide comprises: i) the CRISPR-Cas effector polypeptide; and ii) one or more heterologous fusion partners;
b) a guide RNA comprising i) a targeting region that comprises a nucleotide sequence that binds to a target sequence in the target nucleic acid; and ii) a protein-binding region that binds to the CRISPR-Cas effector polypeptide; and
c) a donor nucleic acid comprising a poison exon insertion nucleotide sequence that provides for insertion of a poison exon into the target nucleic acid, wherein the poison exon insertion nucleotide sequence has a length of from about 21 nucleotides to about 150 nucleotides and comprises, from 5′ to 3′:
i) a nucleotide sequence of from about 5 nucleotides to about 15 nucleotides in length and having a first consensus splice motif;
ii) a nucleotide sequence of from about 11 nucleotides to about 15 nucleotides in length and comprising a stop codon in each reading frame; and
iii) a nucleotide sequence of from about 5 nucleotides to about 15 nucleotides in length and having a second consensus splice motif.

### Claim at position 23

28-29. (canceled)

### Claim 30 (depends on 27)

The system of claim 27, wherein the one or more heterologous polypeptides comprises a reverse transcriptase and wherein the guide RNA comprises a primer binding nucleotide sequence, and optionally wherein the CRISPR-Cas effector polypeptide is a nickase.

### Claim at position 25

31-32. (canceled)

### Claim 33

A composition comprising:
a) a CRISPR-Cas effector polypeptide, or a nucleic acid encoding a CRISPR-Cas effector polypeptide, or a CRISPR-Cas effector fusion polypeptide, or a nucleic acid encoding a CRISPR-Cas effector fusion polypeptide, wherein the CRISPR-Cas effector fusion polypeptide comprises: i) the CRISPR-Cas effector polypeptide; and ii) one or more heterologous fusion partners;
b) a guide RNA comprising i) a targeting region that comprises a nucleotide sequence that binds to a target sequence in the target nucleic acid; and ii) a protein-binding region that binds to the CRISPR-Cas effector polypeptide; and
c) a donor nucleic acid comprising a poison exon insertion nucleotide sequence that provides for insertion of a poison exon into the target nucleic acid, wherein the poison exon insertion nucleotide sequence has a length of from about 21 nucleotides to about 150 nucleotides and comprises, from 5′ to 3′:
i) a nucleotide sequence of from about 5 nucleotides to about 15 nucleotides in length and having a first consensus splice motif;
ii) a nucleotide sequence of from about 11 nucleotides to about 15 nucleotides in length and comprising a stop codon in each reading frame; and
iii) a nucleotide sequence of from about 5 nucleotides to about 15 nucleotides in length and having a second consensus splice motif.

### Claim 34

(canceled)

### Claim 35 (depends on 33)

The composition of claim 33, wherein:
the one or more heterologous polypeptides comprises a reverse transcriptase and wherein the guide RNA comprises a primer binding nucleotide sequence; or
the one or more heterologous polypeptides comprises a cytidine deaminase or an adenosine deaminase.

### Claim at position 29

36-37. (canceled)
